Table III.
Comparison of laboratory data and pomalidomide treatment data between age categories.
| Age categories (years) | ||||
|---|---|---|---|---|
| Factors | <70 | 70–75 | >75 | P-value |
| Number of patients | 2 | 7 | 5 | 0.39 |
| ECOG performance status | 1 [0-1] | 2 [0-3] | 1 [0-3] | 0.29 |
| Time from diagnosis, median (years) | 4.0 [1.6–6.3] | 1.7 [0.7–14.2] | 3.2 [0.8–9.3] | 0.85 |
| Prior treatment regimens | 3 [2-3] | 3 [2-6] | 3 [1-7] | 0.82 |
| Laboratory data at initiation of pomalidomide treatment | ||||
| eGFR (ml/min/1.73 m2) | 64.2 [29.1–99.2] | 57.1 [13.9–101.3] | 64.6 [42.7–81.4] | 0.93 |
| WBC (per µl) | 3,955 [2,980-4,930] | 4,950 [2,830-7,040] | 3,420 [2,300-8,380] | 0.74 |
| Neutrophils (per µl) | 2,531 [1,788-3,352] | 2,871 [1,330-5,914] | 2,155 [1,035-5,698] | 0.79 |
| Hemoglobin (g/µl) | 9.5 [7.6–11.4] | 9.2 [6.9–11.9] | 9.5 [8.8–10.6] | 0.99 |
| Platelets (×104 per µl) | 15.3 [15.2–15.3] | 13.5 [7.2–29.9] | 11.5 [6.1–25.8] | 0.79 |
| Pomalidomide treatment | ||||
| Exposure to pomalidomide (months) | 12 [9-12] | 4 [1-14] | 3 [1-11] | 0.12 |
| Number of treatment cycles | 9 [5-13] | 3 [1-13] | 3 [1-12] | 0.39 |
| Daily treatment dose (mg/day) (n=68) | 4 [2-4] | 3 [3-4] | 3 [1-4] | <0.01 |
| Initiation treatment dose (mg/day) (n=14) | 4 [4-4] | 4 [3-4] | 4 [2-4] | 0.26 |
| Dose reduction of pomalidomide | 1 (50.0) | 2 (28.6) | 3 (60.0) | 0.12 |
| Dose interruption of pomalidomide | 2 (100.0) | 2 (28.6) | 3 (60.0) | 0.12 |
| Overall discontinuation of pomalidomide | 1 (50.0) | 2 (28.6) | 1 (20.0) | 0.74 |
ECOG, eastern cooperative oncology group; eGFR, estimated glomerular filtration rate; WBC, white blood cell. Data are presented as n (%) or median [range].